8-K: Viking Therapeutics Changes Accounting Firms Following Acquisition

Viking Therapeutics replaces Marcum LLP with CBIZ CPAs P.C. as its independent registered public accounting firm due to CBIZ's acquisition of Marcum's attest business.

Summary

• Viking Therapeutics has changed its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C.
• This change was prompted by CBIZ's acquisition of Marcum's attest business on November 1, 2024.
• Marcum resigned on April 18, 2025, and the Audit Committee approved the appointment of CBIZ on April 22, 2025.
• Marcum's reports on the company's financial statements for the years ended December 31, 2024, and December 31, 2023, did not contain any adverse opinions, disclaimers, qualifications, or modifications.
• There were no disagreements or reportable events between Viking Therapeutics and Marcum during the relevant periods.
• Viking Therapeutics intends to file a revised proxy statement for its 2025 annual meeting of stockholders to reflect the change in accounting firms.
• The annual meeting of stockholders is scheduled for May 20, 2025.
• CBIZ will prepare the report on the company's consolidated financial statements for the fiscal year ending December 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The change in accounting firms is a procedural matter and doesn't inherently reflect on the company's performance. The absence of disagreements with the previous firm is a positive sign.

Positives

• Marcum's audit reports for the fiscal years 2023 and 2024 were clean, with no adverse opinions or qualifications, indicating sound financial reporting during their tenure.
• The transition to CBIZ appears to be smooth, with no reported disagreements or reportable events.

Risks

• The change in accounting firms could potentially lead to increased scrutiny or questions from investors until CBIZ establishes a track record with Viking Therapeutics.
• There is a risk of unforeseen issues arising during the transition, although none are indicated in the filing.

Future Outlook

The company intends to file a revised proxy statement for its 2025 annual meeting of stockholders to reflect the change in accounting firms.

Industry Context

Changes in accounting firms are not uncommon, especially following mergers and acquisitions within the accounting industry. Companies routinely update their proxy statements and SEC filings to reflect such changes, ensuring transparency for investors.

Comparison to Industry Standards

• The process of changing accounting firms due to an acquisition is standard practice.
• Many companies, such as Pfizer and Merck, have changed auditors following mergers or acquisitions of their previous audit firms.
• The disclosure provided by Viking Therapeutics is consistent with SEC requirements and industry norms for reporting such changes.

Stakeholder Impact

• Shareholders will receive updated information regarding the company's independent auditor in the revised proxy statement.
• The change in accounting firms is unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Next Steps

• Filing of a revised proxy statement for the 2025 annual meeting of stockholders.
• CBIZ will prepare the report on the company's consolidated financial statements for the fiscal year ending December 31, 2025.

Key Dates

Keywords

accounting firm, CBIZ, Marcum, independent auditor, audit committee, financial statements, Viking Therapeutics